Elsevier

Respiratory Medicine

Volume 105, Issue 6, June 2011, Pages 818-827
Respiratory Medicine

Review
Treatment of pulmonary arterial hypertension: The role of prostacyclin and prostaglandin analogs

https://doi.org/10.1016/j.rmed.2010.12.018Get rights and content
Under an Elsevier user license
open archive

Summary

Pulmonary arterial hypertension is a progressive, fatal disease characterized by elevated pulmonary arterial pressure ≥25 mm Hg and normal pulmonary capillary wedge pressure ≤15 mm Hg. Physiological features of pulmonary arterial hypertension are characterized clinically by the presence of pre-capillary pulmonary hypertension not caused by other conditions such as lung diseases or chronic thromboembolic pulmonary hypertension. There are several therapies currently available that have been shown to improve hemodynamics and improve outcomes in patients with pulmonary arterial hypertension. These therapies include synthetic prostacyclin and prostaglandin analogs, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors. Multiple prostacyclin and prostaglandin analog formulations are currently in use (both branded and generic), available for parenteral, inhaled, or oral administration. This review discusses the pharmacology, clinical effects, and routes of administration of prostacyclin and prostaglandin analogs, emphasizing the advantages and disadvantages of each from the clinical perspective.

Keywords

Epoprostenol
Iloprost
Right heart failure
Treprostinil
6-Minute walk test distance

Cited by (0)